Targeting slow-proliferating ovarian cancer cells

Area of Science:

• Oncology
• Cancer Cell Biology
• Pharmacology

Background:

• Advanced ovarian cancer frequently recurs and has high mortality despite initial chemosensitivity.
• Conventional chemotherapies target rapidly dividing cells, potentially allowing slow-proliferating or quiescent cells to survive and cause relapse.

Purpose of the Study:

• To identify drugs effective against quiescent ovarian cancer cells.
• To investigate the impact of these cells on patient outcomes in advanced ovarian cancer.

Main Methods:

• Screened 44,657 compounds on the NCI-60 panel to find drugs effective against slower-proliferating cells.
• Validated candidates by comparing efficacy with Cisplatin/Paclitaxel and manipulating cell proliferation via serum deprivation.
• Assessed cytostatic/cytocidal effects and measured Ki-67 proliferation indices in patient tumors.

Main Results:

• UCN-01 efficacy correlated with longer cell doubling times, unlike Cisplatin and Paclitaxel.
• UCN-01 showed increased cytostatic and cytocidal effects in serum-deprived (quiescent) cells.
• Low tumor proliferation index was linked to persistent disease and poorer survival (disease-free and overall).

Conclusions:

• Quiescent ovarian cancer cells are associated with poor prognosis.
• Targeting these quiescent cells, potentially with drugs like UCN-01, may offer a novel therapeutic strategy to improve survival in advanced ovarian cancer.